GenMark Diagnostics, Inc (GNMK) Shares Bought by Citadel Advisors LLC

Share on StockTwits

Citadel Advisors LLC lifted its position in GenMark Diagnostics, Inc (NASDAQ:GNMK) by 92.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 126,784 shares of the medical equipment provider’s stock after purchasing an additional 60,991 shares during the quarter. Citadel Advisors LLC owned about 0.23% of GenMark Diagnostics worth $808,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Donaldson Capital Management LLC increased its holdings in shares of GenMark Diagnostics by 22.2% in the second quarter. Donaldson Capital Management LLC now owns 83,003 shares of the medical equipment provider’s stock worth $530,000 after purchasing an additional 15,075 shares during the period. Thrivent Financial for Lutherans increased its holdings in shares of GenMark Diagnostics by 1.3% in the first quarter. Thrivent Financial for Lutherans now owns 596,762 shares of the medical equipment provider’s stock worth $3,246,000 after purchasing an additional 7,792 shares during the period. Penn Capital Management Co. Inc. increased its holdings in shares of GenMark Diagnostics by 8.0% in the second quarter. Penn Capital Management Co. Inc. now owns 455,077 shares of the medical equipment provider’s stock worth $2,903,000 after purchasing an additional 33,644 shares during the period. A.R.T. Advisors LLC increased its holdings in shares of GenMark Diagnostics by 159.4% in the first quarter. A.R.T. Advisors LLC now owns 130,214 shares of the medical equipment provider’s stock worth $708,000 after purchasing an additional 80,024 shares during the period. Finally, Commonwealth Equity Services LLC bought a new position in shares of GenMark Diagnostics in the second quarter worth $115,000. 99.47% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have recently weighed in on GNMK shares. BidaskClub cut shares of GenMark Diagnostics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 11th. Canaccord Genuity upped their price target on shares of GenMark Diagnostics from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, July 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of GenMark Diagnostics in a report on Tuesday, July 31st. Zacks Investment Research cut shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a report on Wednesday, July 18th. Finally, ValuEngine raised GenMark Diagnostics from a “strong sell” rating to a “sell” rating in a research note on Friday, August 10th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. GenMark Diagnostics presently has an average rating of “Hold” and a consensus price target of $11.00.

GNMK opened at $7.91 on Friday. The firm has a market capitalization of $447.14 million, a P/E ratio of -6.54 and a beta of 0.90. The company has a current ratio of 2.04, a quick ratio of 1.80 and a debt-to-equity ratio of 0.19. GenMark Diagnostics, Inc has a 52 week low of $3.63 and a 52 week high of $9.93.

GenMark Diagnostics (NASDAQ:GNMK) last released its earnings results on Monday, July 30th. The medical equipment provider reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.09). The firm had revenue of $14.94 million during the quarter, compared to the consensus estimate of $14.74 million. GenMark Diagnostics had a negative net margin of 91.58% and a negative return on equity of 87.96%. sell-side analysts anticipate that GenMark Diagnostics, Inc will post -0.85 earnings per share for the current fiscal year.

In related news, insider Hany Massarany sold 6,010 shares of the stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $7.39, for a total value of $44,413.90. Following the transaction, the insider now owns 688,694 shares of the company’s stock, valued at $5,089,448.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 20,230 shares of company stock worth $147,242. 7.50% of the stock is owned by insiders.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

See Also: What is the NASDAQ?

Institutional Ownership by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Head to Head Comparison: Bright Scholar Education Holdngs  versus K12
Head to Head Comparison: Bright Scholar Education Holdngs versus K12
GenMark Diagnostics, Inc  Shares Bought by Citadel Advisors LLC
GenMark Diagnostics, Inc Shares Bought by Citadel Advisors LLC
Contrasting Alibaba Group  & NetEase
Contrasting Alibaba Group & NetEase
ING Groep NV Trims Stake in UnitedHealth Group Inc
ING Groep NV Trims Stake in UnitedHealth Group Inc
Head-To-Head Survey: Telstra  versus Inventergy Global
Head-To-Head Survey: Telstra versus Inventergy Global
Citadel Advisors LLC Has $832,000 Stake in SJW Group
Citadel Advisors LLC Has $832,000 Stake in SJW Group


Leave a Reply

© 2006-2018 Ticker Report. Google+.